TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Neeraj  Agarwal

Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen

Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)

Arun  Azad

Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar

Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar

Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis

Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)

Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar

Joan  Carles

Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZéneca; Bayer; Bristol-Myers Squibb; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Roche; Sanofi

Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson

Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera; Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag International NV (Inst); Karyopharm Therapeutics (Inst); Laboratories Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)

Travel, Accommodations, Expenses - AstraZeneca; BMS; Ipsen; Roche

Andre P.  Fay

Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD; Novartis; Pfizer; Roche

Consulting or Advisory Role - AstraZeneca; Ipsen; Merck Sharp & Dohme; Novartis; Pfizer; Roche

Nobuaki  Matsubara

Honoraria - Sanofi

Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen

Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)

Daniel  Heinrich

Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Novartis; Pfizer; Sanofi

Consulting or Advisory Role - Bayer; Eisai

Research Funding - AstraZeneca (Inst); Eisai (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)

Cezary  Szczylik

No Relationships to Disclose

Ugo  De Giorgi

Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dompé Farmaceutici; Eisai; Ipsen; Janssen; Merck KGaA; MSD; Novartis; Pfizer; PharmaMar

Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)

Travel, Accommodations, Expenses - Ipsen; Pfizer

Jae Young  Joung

Honoraria - Astellas Pharma; Johnson & Johnson/Janssen; Sanofi/Aventis

Peter C.C.  Fong

Consulting or Advisory Role - MSD

Travel, Accommodations, Expenses - Pfizer

Eric  Voog

No Relationships to Disclose

Robert J  Jones

No Relationships to Disclose

Neal D.  Shore

Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Photocure; Propella Therapeutics; Sanofi; Sema4; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tempus; Tolmar; Urogen pharma; Vaxiion

Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer

Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; Seagen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow

Expert Testimony - Ferring

Other Relationship - Alessa Therapeutics; Photocure

Curtis  Dunshee

Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen Biotech; Pfizer

Research Funding - AstraZeneca (Inst); Dendreon (Inst); Eleven Biotherapeutics (Inst); Hengrui Pharmaceutical (Inst); Janssen Oncology (Inst); Laekna Therapeutics (Inst); Myovant Sciences (Inst); pfizer (Inst); Tavanta Therapeutics (Inst)

Stefanie  Zschaebitz

Consulting or Advisory Role - Amgen; Bristol-Myers Squibb (Inst); Eisai; EUSA Pharma; Merck; MSD Oncology; Pfizer (Inst); Roche; Sanofi/Aventis (Inst)

Research Funding - Eisai (Inst)

Travel, Accommodations, Expenses - Merck; Pfizer

Xun  Lin

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Cynthia G.  Healy

Employment - Pfizer; PRA Health Sciences (I)

Stock and Other Ownership Interests  - Pfizer

Travel, Accommodations, Expenses - Pfizer

Nicola  Di Santo

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Fabian  Zohren

Employment - Pfizer

Stock and Other Ownership Interests  - AlloVir (I); Pfizer

Patents, Royalties, Other Intellectual Property - AlloVir Inc (I)

Karim  Fizazi

Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)

Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer; Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); ESSA (Inst); Janssen Oncology (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Janssen; MSD